# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
JP Morgan analyst Jessica Fye maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Neutral and raises the price target fro...
June saw gains in the U.S. stock market, with tech and biotech leading the way. Semiconductor ETFs saw strong inflows, while ut...
Cantor Fitzgerald analyst Olivia Brayer reiterates Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Neutral and maintains $150 p...
The top 10 large-cap stocks in the last week were RIVN, CUK, FDX, IOT, SUZ, CVNA, FTAI, RDDT, MDB, and ALNY. Many analysts have...
UBS analyst Eliana Merle maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and raises the price target from $253 to...
RBC Capital analyst Luca Issi maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform and raises the price target ...